SB269970盐酸盐 | 201038-74-6

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: SB269970盐酸盐
• 中文别名: SB 269970盐酸盐
• 英文名称: (R)-3-((2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)phenol
• 英文别名: 3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol
• CAS: 201038-74-6
• 化学式: C₁₈H₂₈N₂O₃S
• 分子量: 352.5
• InChiKey: HWKROQUZSKPIKQ-MRXNPFEDSA-N

物化性质

• 沸点：
  512.9±56.0 °C(Predicted)
• 密度：
  1.188
• 溶解度：
  H2O: 22 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  69.2
• 氢给体数：
  1
• 氢受体数：
  5

制备方法与用途

生物活性

SB269970 是 5-HT7 受体的拮抗剂，其 pKi 值为 8.3。对于其他受体而言，它具有大于 50 倍的选择性。

靶点

• Human 5-HT7 Receptor
• pKi: 8.3

体内研究

SB269970 (3-30 mg/kg, i.p., once) 显著阻断了安非他明和氯胺酮诱导的活动亢进。

实验细节

动物模型：	雄性 C57BL6/J 小鼠
剂量：	3, 10, 30 mg/kg
给药方式：	腹腔注射；一次给药
结果：	显著阻断了安非他明和氯胺酮诱导的活动亢进。

文献信息

• Synthesis by chiral diamine-mediated asymmetric alkylation
  申请人：Deng Xiaohu

  公开号：US20060069250A1

  公开（公告）日：2006-03-30

  Chiral synthesis from an achiral starting material by chiral diamine-mediated, such as sparteine-mediated, intermolecular asymmetric alkylation with a strained cyclic ether in the presence of a Lewis acid.

  在Lewis酸存在的情况下，通过手性二胺介导的手性合成（例如sparteine介导），从非手性起始物质进行分子间不对称烷基化，使用受限环醚。
• Therapeutic agent for intestinal diseases and visceral pain
  申请人：Tokumasu Munetaka

  公开号：US20050148632A1

  公开（公告）日：2005-07-07

  The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect and a high safety:

  本发明涉及一种治疗腹泻型肠易激综合征、溃疡性结肠炎、内脏疼痛或腹痛的治疗剂，其含有以下公式的化合物或其类似物，具有5-HT7受体拮抗作用；该治疗剂具有优异的治疗效果和高安全性：
• Pyrrole Derivative or Salt Thereof
  申请人：Seo Ryushi

  公开号：US20090036421A1

  公开（公告）日：2009-02-05

  [Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT 2B receptor and 5-HT 7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).

  [问题] 提供一种可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病，特别是治疗肠易激综合征（IBS）的化合物。 [解决方案] 发现一种吡咯衍生物，在其3位具有胍基甲酰基基团或酰胺基团作为取代基团，或其药学上可接受的盐，具有对5-HT2B受体和5-HT7受体的强拮抗作用。此外，与仅使用对其中一种受体选择性拮抗剂相比，具有对两种受体拮抗活性的本发明化合物显示出良好的药理作用。基于上述，本发明化合物对于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病，特别是治疗肠易激综合征（IBS）是有用的。
• Flourene Derivative
  申请人：Yamada Hiroyoshi

  公开号：US20080200551A1

  公开（公告）日：2008-08-21

  This invention relates to a novel fluorene derivative having a characteristic structure in which guanidino group or the like functional group is linked to the fluorene structure via carbonyl group, or a salt thereof. The compound of the invention has an advantage in that it has high affinity for serotonin receptor subtypes, particularly for 5-HT 2B receptor and 5-HT 7 receptor, and shows excellent pharmacological effects in comparison with the conventional compounds which have only one of the antagonistic activities of 5-HT 2B receptor and 5-HT 7 receptor, this is useful as a prophylactic antimigraine agent having high safety and excellent effect.

  这项发明涉及一种新颖的芴衍生物，其具有特征结构，其中脲基或类似的官能团通过羰基与芴结构连接，或其盐。该化合物具有优点，即它对5-HT2B受体和5-HT7受体等血清素受体亚型具有高亲和力，并与仅具有5-HT2B受体和5-HT7受体拮抗活性之一的传统化合物相比，显示出出色的药理效应，因此可用作具有高安全性和出色效果的预防性抗偏头痛剂。
• AMIDE DERIVATIVE OR SALT THEREOF
  申请人：Kaku Hidetaka

  公开号：US20090062363A1

  公开（公告）日：2009-03-05

  [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that an amide derivative characterized by the possession of a nitrogen-containing bicyclic hetero ring (e.g., an indole or the like), or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT 2B receptor and 5-HT 7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).

  [问题] 提供一种可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病的化合物，特别是用于治疗肠易激综合征（IBS）。 [解决方法] 发现一种具有含氮双环杂环（例如吲哚或类似物）的酰胺衍生物或其药学上可接受的盐具有强烈的5-HT2B受体和5-HT7受体的拮抗作用。此外，本发明的化合物具有对两种受体的拮抗活性，与仅使用选择性拮抗剂相比，表现出良好的药理作用。基于上述，本发明的化合物可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病，特别是用于治疗肠易激综合征（IBS）。